From: The association between serum adiponectin and 3-month outcome after ischemic stroke
 | Total | Good outcomes | Poor outcomes | Pa |
---|---|---|---|---|
N | 227 | 169 | 58 | – |
Age, years | 64 (53–72) | 62 (51–70) | 71 (62–83) | 0.009 |
Sex-male | 128 (56.4) | 94 (55.6) | 34 (58.6) | 0.69 |
BMI, kg/m2 | 24.2 (22.8–26.4) | 24.0 (22.7–26.3) | 24.5 (23.2–26.8) | 0.38 |
Prior vascular risk factors, n (%) | ||||
 Hypertension | 145 (63.9) | 102 (60.4) | 43 (74.1) | 0.059 |
 Hypercholesterolemia | 68 (30.0) | 49 (29.0) | 19 (32.8) | 0.59 |
 Coronary heart disease | 57 (25.1) | 42 (24.9) | 15 (25.9) | 0.88 |
 Atrial fibrillation | 49 (21.6) | 31 (18.3) | 18 (31.0) | 0.043 |
 Diabetes mellitus | 53 (23.3) | 38 (22.5) | 15 (25.9) | 0.60 |
 Previous TIA | 25 (11.0) | 17 (10.1) | 8 (13.8) | 0.43 |
 Smoking | 55 (24.2) | 40 (23.7) | 15 (25.9) | 0.74 |
Pre-stroke treatment, n (%) | ||||
 Antihypertensive treatment | 130 (57.3) | 95 (56.2) | 35 (60.3) | 0.58 |
 Antidiabetic | 31 (13.7) | 23 (13.6) | 8 (13.8) | 0.97 |
 Antiplatelet agents | 72 (31.7) | 52 (30.8) | 20 (34.5) | 0.60 |
 Anticoagulants | 23 (10.1) | 18 (10.7) | 5 (8.6) | 0.66 |
 Statins | 51 (22.5) | 37 (21.9) | 14 (24.1) | 0.72 |
Acute treatment, n (%) | ||||
 IV thrombolysis | 27 (11.9) | 26 (15.4) | 1 (1.7) | 0.011 |
 Mechanical thrombectomy | 17 (7.5) | 16 (9.5) | 1 (1.7) | 0.053 |
Stroke etiology, n (%) | ||||
 Small-vessel occlusive | 33 (14.5) | 26 (15.4) | 7 (12.1) | 0.54 |
 Large-vessel occlusive | 41 (18.1) | 31 (18.3) | 10 (17.2) | 0.85 |
 Cardioembolic | 75 (33.0) | 56 (33.1) | 19 (32.8) | 0.96 |
 Other | 15 (6.6) | 11 (6.5) | 4 (6.9) | 0.92 |
 Unknown | 63 (27.8) | 45 (26.6) | 18 (31.0) | 0.52 |
Stroke severity, NIHSS at admission | 6 (2–11) | 5 (1–9) | 9 (5–15) | < 0.001 |
DWI lesion, ml | 15.2 (8.5–26.5) | 13.2 (7.1–21.4) | 20.9 (11.3–33.7) | < 0.001 |
Laboratory findings | ||||
 Glucose level, mmol/l | 5.95 (5.53–6.63) | 5.73 (5.35–6.33) | 6.35 (5.94–7.15) | 0.009 |
 CRP, mg/l | 5.6 (3.0–9.2) | 4.9 (2.5–7.9) | 7.0 (4.7–11.7) | < 0.001 |
 Adiponectin, μg/ml | 7.0 (4.4–10.0) | 6.3 (4.0–8.9) | 10.0 (7.0–13.9) | < 0.001 |
Stroke syndrome | ||||
 TACS | 24 (10.6) | 10 (5.9) | 14 (24.1) | < 0.001 |
 PACS | 96 (42.3) | 72 (42.6) | 24 (41.4) | 0.87 |
 LACS | 54 (23.8) | 37 (21.9) | 17 (29.3) | 0.25 |
 POCS | 53 (23.3) | 50 (29.6) | 3 (5.2) | < 0.001 |